Date: 2011-03-02
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of two studies
Company: Allergan (USA) Syntaxin (UK)
Product: AGN-214868 (senrebotase)
Action mechanism:
Disease:
Therapeutic area: CNS diseases - Urology
Country:
Trial
details: patients with post herpetic neuralgia (PHN) and overactive bladder
Latest
news: * On March 2, 2011, Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, has announced its partner Allergan Inc has initiated two Phase II trials to evaluate the safety and efficacy of its re?targeted endopeptidase drug candidate AGN-214868. The Phase II trials will be focused on patients with post herpetic neuralgia (PHN) and overactive bladder.
AGN-214868 was discovered under the collaboration using Syntaxin’s proprietary discovery platform. Under this agreement, Allergan is responsible for the clinical development, marketing and sales of identified drug candidates. Syntaxin receives milestone payments and royalties on productsales.
